Protocol for the Stimulating β(3)-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease

INTRODUCTION: There is currently only one approved medication effective at improving walking distance in people with intermittent claudication. Preclinical data suggest that the β(3)-adrenergic receptor agonist (mirabegron) could be repurposed to treat intermittent claudication associated with perip...

Descripción completa

Detalles Bibliográficos
Autores principales: Bubb, Kristen J, Harmer, Jason A, Finemore, Meghan, Aitken, Sarah Joy, Ali, Zara S, Billot, Laurent, Chow, Clara, Golledge, Jonathan, Mister, Rebecca, Gray, Michael P, Grieve, Stuart M, Hamburg, Naomi, Keech, Anthony C, Patel, Sanjay, Puttaswamy, Vikram, Figtree, Gemma A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479946/
https://www.ncbi.nlm.nih.gov/pubmed/34588252
http://dx.doi.org/10.1136/bmjopen-2021-049858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479946/
https://www.ncbi.nlm.nih.gov/pubmed/34588252
http://dx.doi.org/10.1136/bmjopen-2021-049858

Ejemplares similares